RATIONALE: Pharmacogenetic studies on antipsychotic-induced movement disorders (MD) in schizophrenia so far have focused mainly on tardive dyskinesia. Only a few examined the more acute antipsychotic-induced MD such as parkinsonism and akathisia. Notably, all MD relate to deregulation of the dopamine system. OBJECTIVE: This study aimed to replicate previously reported associations in candidate genes for acute and tardive antipsychotic-induced MD in a young Caucasian sample. METHODS: In 402 patients (median age 26 years), a total of 13 polymorphisms were genotyped in eight dopamine-related candidate genes selected a priori from the literature (regarding dopamine and serotonin receptors, dopamine degradation, and free radicals scavenging enzymes pathways). RESULTS: Patients with MD used on average a higher haloperidol dose equivalent when compared to those without MD. The prevalence of MD was high and did not differ between first- and second-generation antipsychotics. Significant associations were found between (a) the TaqI_D polymorphism and akathisia (OR = 2.3, p = 0.001 for each extra C-allele) and (b) the -141C polymorphism and tardive dyskinesia (OR = 0.20, p = 0.001 for each extra Del allele). The other polymorphisms were not significantly associated with an MD. CONCLUSIONS: Two associations were found between genetic variation TaqI_D and the -141C polymorphisms in the DRD2 gene and antipsychotic-induced MD; one with acute akathisia and one with tardive dyskinesia. These were previously reported to be associated with tardive dyskinesia and acute parkinsonism, respectively. These results suggest that the contribution of these DRD2 gene variants in the vulnerability of antipsychotic-induced MD takes place in a more general or pleiotropic way.
RATIONALE: Pharmacogenetic studies on antipsychotic-induced movement disorders (MD) in schizophrenia so far have focused mainly on tardive dyskinesia. Only a few examined the more acute antipsychotic-induced MD such as parkinsonism and akathisia. Notably, all MD relate to deregulation of the dopamine system. OBJECTIVE: This study aimed to replicate previously reported associations in candidate genes for acute and tardive antipsychotic-induced MD in a young Caucasian sample. METHODS: In 402 patients (median age 26 years), a total of 13 polymorphisms were genotyped in eight dopamine-related candidate genes selected a priori from the literature (regarding dopamine and serotonin receptors, dopamine degradation, and free radicals scavenging enzymes pathways). RESULTS:Patients with MD used on average a higher haloperidol dose equivalent when compared to those without MD. The prevalence of MD was high and did not differ between first- and second-generation antipsychotics. Significant associations were found between (a) the TaqI_D polymorphism and akathisia (OR = 2.3, p = 0.001 for each extra C-allele) and (b) the -141C polymorphism and tardive dyskinesia (OR = 0.20, p = 0.001 for each extra Del allele). The other polymorphisms were not significantly associated with an MD. CONCLUSIONS: Two associations were found between genetic variation TaqI_D and the -141C polymorphisms in the DRD2 gene and antipsychotic-induced MD; one with acute akathisia and one with tardive dyskinesia. These were previously reported to be associated with tardive dyskinesia and acute parkinsonism, respectively. These results suggest that the contribution of these DRD2 gene variants in the vulnerability of antipsychotic-induced MD takes place in a more general or pleiotropic way.
Authors: R H Segman; U Heresco-Levy; B Finkel; T Goltser; R Shalem; M Schlafman; A Dorevitch; A Yakir; D Greenberg; A Lerner; B Lerer Journal: Mol Psychiatry Date: 2001-03 Impact factor: 15.992
Authors: E G Jönsson; M M Nöthen; F Grünhage; L Farde; Y Nakashima; P Propping; G C Sedvall Journal: Mol Psychiatry Date: 1999-05 Impact factor: 15.992
Authors: Ismail Al-Janabi; Maria J Arranz; Alexandra I F Blakemore; Pilar A Saiz; Margaret T Susce; Paul E A Glaser; Daniel Clark; Jose de Leon Journal: Psychiatr Genet Date: 2009-12 Impact factor: 2.458
Authors: Bernard Lerer; Ronnen H Segman; Heiner Fangerau; Ann K Daly; Vincenzo S Basile; Roberto Cavallaro; Harald N Aschauer; Robin G McCreadie; Stephanie Ohlraun; Nicol Ferrier; Mario Masellis; Massimiliano Verga; Joachim Scharfetter; Marcella Rietschel; Roger Lovlie; Uriel Heresco Levy; Herbert Y Meltzer; James L Kennedy; Vidar M Steen; Fabio Macciardi Journal: Neuropsychopharmacology Date: 2002-07 Impact factor: 7.853
Authors: P Roberto Bakker; Egbert Bakker; Najaf Amin; Cornelia M van Duijn; Jim van Os; Peter N van Harten Journal: PLoS One Date: 2012-05-15 Impact factor: 3.240
Authors: P Roberto Bakker; Asmar F Y Al Hadithy; Najaf Amin; Cornelia M van Duijn; Jim van Os; Peter N van Harten Journal: PLoS One Date: 2012-12-04 Impact factor: 3.240
Authors: Irene M Lako; Johanna T W Wigman; Rianne M C Klaassen; Cees J Slooff; Katja Taxis; Agna A Bartels-Velthuis Journal: BMC Psychiatry Date: 2014-09-03 Impact factor: 3.630